Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: Results from a six-month prospective, multinational, observational study

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 3, 2009, Pages 729-740

  Treuer, Tamás ^a   Hoffmann, Vicki Poole ^b   Chen, Antony Kuang Peng ^c   Irimia, Victoria ^d   Ocampo, Magdalena ^e   Wang, Gang ^f   Singh, Pritibha ^g   Holt, Susanna ^g  

^a Neuroscience Research   (Hungary)

^b ELI LILLY AND COMPANY   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d Endocrinology Department   (Romania)

^e Centro de Investigacin Farmacolgica y Biotecnolgica   (Mexico)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g ELI LILLY AUSTRALIA PTY LTD   (Australia)

Author keywords

Antipsychotics; Bipolar disorder; Olanzapine; Schizophrenia; Weight gain

Indexed keywords

OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; EXERCISE; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; WEIGHT CHANGE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; HEALTH STATUS; HOSPITALIZATION; INTERNATIONAL COOPERATION; LIFESTYLE; MULTICENTER STUDY; OBESITY; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEEDING BEHAVIOR; FEMALE; HEALTH STATUS; HUMANS; INTERNATIONAL COOPERATION; LIFE STYLE; MALE; OBESITY; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; WEIGHT GAIN;

EID: 77949511943     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970903079507     Document Type: Article

References (28)

1. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. 1999. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 60:215-220.
2. Allison DB, Casey DE. 2001. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62(Suppl 7):22-31.
3. Baptista T, Kin NMKNY, Beaulieu S, de Baptista EA. 2002. Obesity and related metabolic abnormalities during antipsychotic administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205-219.
4. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. 2001. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, halo-peridol, or risperidone. J Clin Psychiatry 62:231-238.
5. Elsmlie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. 2000. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 61:179-184.
6. Evans S, Newton R, Higgins S. 2005. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust NZ J Psychiatry 39:479-486
7. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, et al. 2002. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159:1055-1057.
8. Guy W 1976. Clinical global impression. In: Guy W ECDEU Assessment Manual for Psychopharmacology (revised). Publication ADM 76-338. Bethesda, MD: US Department of Health, Education, and Welfare. pp 217-221.
9. Haddad PM, Sharma SG. 2007. Adverse effects of atypical antipsychotics. Differential risk and clinical implications. CNS Drugs 21:911-936.
10. Jones B, Basson BR, Walker DJ, Crawford AMK, Kinon BJ. 2001. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 62(Suppl 2):41-44.
11. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. 2001. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62:92-100.
12. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. 2005. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25:255-258.
13. Kwon JS, Choi JS, Bahk WM, Kim CY, Kim CH, Shin YC, et al. 2006. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J Clin Psychiatry 67:547-553.
14. Lipkovich I, Citrome L, Perlis R, Deberdt W, Houston JP, Ahl J, et al. 2006. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharma-col 26:316-320.
15. Lipkovich I, Jacobson JG, Hardy TA, Poole Hoffmann V. 2008. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry 8:78.
16. Marder SR, Noordsy DL, Glynn SM, O'Keefe C, Almeida MA 2006. Two year outcomes on risperidone and olanzapine in stable patients with schizophrenia. Neuropsychopharmacology 31(Suppl 1):s250(Abstract 131).
17. Mauri M, Simoncini M, Castrogiovanni S, Iovieno N, Cecconi D, Dell'Agnello G, et al. 2008. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry 41:17-23.
18. McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K, Eggleston A. 2003. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry 48:689-694.
19. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, et al. 2007. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind, placebo-controlled study. Psychophar-macology 192:441-448.
20. Rege S. 2008. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust NZ J Psychiatry 42:369-381.
21. Saddichha S, Ameen S, Akhtar S. 2008. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol 28:27-31.
22. Smith E, Rothschild AJ, Heo M, Peasley-Miklus C, Caswell M, Papademetriou E, et al. Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. Int Clin Psychopharmacol 23:130-137.
23. Strassnig M, Miewald J, Keshavan M, Ganguli R. 2007. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 93: 90-98.
24. Taylor DM, McAskill R. 2000. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand 101:416-32.
25. Treuer T, Karagianis J, Poole-Hoffman V. 2008. Can increased food intake improve psychosis? A brief review and hypothesis. Curr Mol Pharmacol 1:270-272.
26. Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, et al. 2008. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 69:1416-1422.
27. WHO Expert Consultation. 2004. Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363:157-163.
28. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, et al. 2005. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 187:537-543.